Amgen reported third-quarter 2026 financial results, showing an 8% increase in total revenues to $10.4 billion compared to the same period in 2025. GAAP earnings per share rose 19% to $7.08, while non-GAAP earnings per share grew 14% to $6.45.
Total revenues for the third quarter of 2026 increased 8% year-over-year to $10.4 billion.
GAAP earnings per share rose 19% to $7.08 for the third quarter of 2026.
Non-GAAP earnings per share increased 14% to $6.45 for the third quarter of 2026.
Full-year 2026 total revenues are expected to be in the range of $38.9 billion to $39.7 billion.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Amgen's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$36.75B
+10.0%
$14.23
+88.2%
21.0%
FY2024
$33.42B
+18.6%
$7.56
-39.5%
12.2%
FY2023
$28.19B
+7.1%
$12.49
+3.1%
23.8%
FY2022
$26.32B
+1.3%
$12.11
+17.8%
24.9%
FY2021
$25.98B
+2.2%
$10.28
-16.5%
22.7%
Frequently asked questions
When is Amgen's next earnings date?
Amgen has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Amgen earn last quarter?
For the quarter ended Sep 2026, Amgen reported diluted EPS of $7.08 (+19.4% year over year) on revenue of $10.37B (+8.5%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.